<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7113931/results/search/test_trace/results.xml">
  <result pre=": Review Article Emerging resistance to directly-acting antiviral therapy in" exact="treatment" post="of chronic Hepatitis C infection—A brief review of literature"/>
  <result pre="virus in 1989, the clinical management of chronic hepatitis C" exact="infection" post="has undergone a paradigm shift from alpha interferon to"/>
  <result pre="to DAAs and the relevance of in vitro DAA resistance" exact="testing" post="in clinical practice. Directly acting antiviral Hepatitis C virus"/>
  <result pre="virus in 1989, the clinical management of chronic hepatitis C" exact="infection" post="has undergone a paradigm shift from alpha interferon to"/>
  <result pre="to DAAs and the relevance of in vitro DAA resistance" exact="testing" post="in clinical practice. Structural organization of Hepatitis C virus"/>
  <result pre="the synthesis of new RNA genome. Natural history of HCV" exact="infection" post="Infection with HCV can present either as acute or"/>
  <result pre="asymptomatic and rarely leads to hepatic failure. Symptomatic acute HCV" exact="infection" post="has a mild clinical course with less than one"/>
  <result pre="of patients presenting with jaundice. About 60–80% patients with acute" exact="infection" post="develop chronic infection.[23] The rate of spontaneous viral clearance"/>
  <result pre="low. Approximately, one fifth (20–30%) of patients with chronic HCV" exact="infection" post="develop cirrhosis over a period of 10–30 years.[24] 1–4%"/>
  <result pre="hepatic coma, and hepatorenal syndrome leading to renal failure. Chronic" exact="infection" post="can also be associated with extra-hepatic manifestations such as"/>
  <result pre="idiopathic thrombocytopenic purpura, and non-Hodgkin's lymphoma.[26] Problem statement The global" exact="prevalence" post="of HCV infection is estimated at 2–3%.[27282930] The prevalence"/>
  <result pre="and non-Hodgkin's lymphoma.[26] Problem statement The global prevalence of HCV" exact="infection" post="is estimated at 2–3%.[27282930] The prevalence of HCV is"/>
  <result pre="global prevalence of HCV infection is estimated at 2–3%.[27282930] The" exact="prevalence" post="of HCV is highest in Africa and the Middle"/>
  <result pre="America, Australia, Japan, and Northern and Western Europe report lower" exact="prevalence" post="of HCV infection, with no country showing a rate"/>
  <result pre="a rate &amp;gt; 2%. Owing to the paucity of large-scale" exact="prevalence" post="studies on hepatitis C in the general population of"/>
  <result pre="hepatitis C in the general population of India, the reported" exact="prevalence" post="rates are variable ranging from 0.09–2.02%.[35] The genetic diversity"/>
  <result pre="and Thailand.[3040414243444546] Treatment of chronic Hepatitis C—An evolutionary perspective The" exact="treatment" post="of chronic hepatitis C virus infection has been rapidly"/>
  <result pre="C—An evolutionary perspective The treatment of chronic hepatitis C virus" exact="infection" post="has been rapidly evolving since early 1990s with interferon-alfa."/>
  <result pre="37 to 43%. In 2002, pegylated interferon-alfa was approved for" exact="treatment" post="of chronic hepatitis C. Combined with ribavirin, permanent response"/>
  <result pre="replication and assembly has ushered a new era in the" exact="treatment" post="of hepatitis C.[50] The DAAs are molecules that target"/>
  <result pre="in drug-targeted genes resulting in reduced susceptibility to DAAs.[57] The" exact="prevalence" post="of intrinsically resistant variants within a patient's quasispecies is"/>
  <result pre="minor populations of resistance-associated variants (RAVs) at the start of" exact="treatment" post="may affect the outcomes of the antiviral therapy. Such"/>
  <result pre="exerted by antiviral drugs, subsequently leading to virological breakthrough during" exact="treatment" post="or relapse after treatment cessation.[58] Some RAVs such as"/>
  <result pre="subsequently leading to virological breakthrough during treatment or relapse after" exact="treatment" post="cessation.[58] Some RAVs such as those conferring resistance to"/>
  <result pre="persist as the dominant species for months to years after" exact="treatment" post="cessation. Understanding drug resistance is important in clinical settings"/>
  <result pre="Understanding drug resistance is important in clinical settings to optimize" exact="treatment" post="regimens, increase success rates, and minimize the impact of"/>
  <result pre="treatment regimens, increase success rates, and minimize the impact of" exact="treatment" post="failure. Table 3 depicts the most common amino acid"/>
  <result pre="Beclabuvir NS5B non-nucleoside polymerase inhibitor A421V, P495L/S 1a Drug resistance" exact="testing" post="in clinical practice-An overview The replication cycle of HCV"/>
  <result pre="regimens. The magnitude of the negative impact of RASs on" exact="treatment" post="outcome varies according to treatment regimen and patient factors"/>
  <result pre="negative impact of RASs on treatment outcome varies according to" exact="treatment" post="regimen and patient factors such as presence of cirrhosis"/>
  <result pre="in clinical practice becomes important when the results would modify" exact="treatment" post="management by impacting the duration of therapy and/or inclusion"/>
  <result pre="of alternative therapy. However, at present the utility of RAS" exact="testing" post="varies by both patient characteristics and DAA regimen. Table"/>
  <result pre="Table 4 depicts the regimen-specific recommendations for use of RAS" exact="testing" post="in clinical practice.[61] Table 4 Regimen-specific recommendations for use"/>
  <result pre="clinical practice.[61] Table 4 Regimen-specific recommendations for use of RAS" exact="testing" post="in clinical practice[61] Recommended *Rating Elbasvir/grazoprevir  NS5A RAS testing"/>
  <result pre="RAS testing in clinical practice[61] Recommended *Rating Elbasvir/grazoprevir  NS5A RAS" exact="testing" post="is recommended for genotype 1a-infected, treatment-naive or -experienced patients"/>
  <result pre="different regimen should be considered. I, A Ledipasvir/sofosbuvir  NS5A RAS" exact="testing" post="can be considered for genotype 1a-infected, treatment-experienced patients without"/>
  <result pre="present, a different recommended therapy should be used.  NS5A RAS" exact="testing" post="can be considered for genotype 1a-infected, treatment-experienced patients with"/>
  <result pre="recommended therapy should be used. I, A Sofosbuvir/velpatasvir  NS5A RAS" exact="testing" post="is recommended for genotype 3-infected, treatment-naive patients with cirrhosis"/>
  <result pre="should be used. I, A Daclatasvir plus sofosbuvir  NS5A RAS" exact="testing" post="is recommended for genotype 3-infected, treatment-experienced patients without cirrhosis"/>
  <result pre="Y93H is present, weight-based ribavirin should be added.  NS5A RAS" exact="testing" post="is recommended for genotype 3-infected, treatment-naive patients with cirrhosis"/>
  <result pre="24 weeks of daclatasvir plus sofosbuvir. If Y93H is present," exact="treatment" post="should include weight-based ribavirin, or a different recommended therapy"/>
  <result pre="different recommended therapy used I, B NOT RECOMMENDED Elbasvir/grazoprevir  RAS" exact="testing" post="is not recommended for any genotype 1b-infected patients being"/>
  <result pre="patients being considered for elbasvir/grazoprevir therapy. I, A Glecaprevir/pibrentasvir  RAS" exact="testing" post="is not recommended for patients with genotype 1, 2,"/>
  <result pre="patients with genotype 1, 2, 3, 4, 5, or 6" exact="infection" post="being considered for glecaprevir/pibrentasvir for 8, 12, or 16"/>
  <result pre="8, 12, or 16 weeks I, A Ledipasvir/sofosbuvir  NS5A RAS" exact="testing" post="is not recommended for any genotype 1b-infected patients being"/>
  <result pre="patients being considered for ledipasvir/sofosbuvir therapy. I, A  NS5A RAS" exact="testing" post="is not recommended for genotype 1a-infected, treatment-naive patients being"/>
  <result pre="patients being considered for ledipasvir/sofosbuvir therapy I, A  NS5A RAS" exact="testing" post="is not recommended for genotype 1a- or 1b-infected, treatment-naive"/>
  <result pre="Paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based ribavirin, or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin  RAS" exact="testing" post="is not recommended for genotype 1- or 4-infected, treatment-naive"/>
  <result pre="or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin, respectively. I, A Sofosbuvir/velpatasvir  RAS" exact="testing" post="is not recommended for patients with genotype 1, 2,"/>
  <result pre="for patients with genotype 1, 2, 4, 5, or 6" exact="infection" post="and considered for 12 weeks of sofosbuvir/velpatasvir therapy. I,"/>
  <result pre="for 12 weeks of sofosbuvir/velpatasvir therapy. I, A Sofosbuvir/velpatasvir/voxilaprevir  RAS" exact="testing" post="is not recommended for patients with genotype 1, 2,"/>
  <result pre="patients with genotype 1, 2, 3, 4, 5, or 6" exact="infection" post="and considered for 12 weeks of sofosbuvir/velpatasvir/voxilaprevir therapy. I,"/>
  <result pre="and/or general agreement that a given diagnostic evaluation, procedure, or" exact="treatment" post="is beneficial, useful, and effective; A: Data derived from"/>
  <result pre="RASs by NGS. However, the presence of RASs with &amp;lt;15%" exact="prevalence" post="should not be considered clinically significant. Phenotypic analysis involves"/>
  <result pre="sequencing of the bulk PCR product. Although the sensitivity for" exact="detection" post="of resistance substitutions is subject to variation, in generally"/>
  <result pre="Analysis/Next Generation Sequencing (NGS): NGS can increase the sensitivity of" exact="detection" post="for minor variants. After sequencing HCV coding regions using"/>
  <result pre="of fitness. Directly acting antiviral therapy and primary healthcare The" exact="treatment" post="and monitoring requirements of regimens containing Direct Acting Antivirals"/>
  <result pre="efficacy in treating HCV infections. These characteristics mean that initiating" exact="treatment" post="and obtaining SVR on completion of treatment in non-specialist"/>
  <result pre="mean that initiating treatment and obtaining SVR on completion of" exact="treatment" post="in non-specialist environments should be feasible.[65] To achieve the"/>
  <result pre="it is essential to increase access to treatment. Hence, DAA" exact="treatment" post="can be provided in primary healthcare services in order"/>
  <result pre="of these studies.[65] Currently in India, few states are providing" exact="treatment" post="and care for HCV infected patients with DAAs and"/>
  <result pre="with DAAs and some healthcare facilities are also providing antiviral" exact="treatment" post="for chronic Hepatitis B infection/disease. The National Viral Hepatitis"/>
  <result pre="order to align with the national protocols and guidance on" exact="testing" post="and management of different types of viral hepatitis (namely"/>
  <result pre="general population, especially high-risk groups and in hotspots. Provide early" exact="diagnosis" post="and management of viral hepatitis at all levels of"/>
  <result pre="hepatitis at all levels of healthcare. Develop standard diagnostic and" exact="treatment" post="protocols for management of viral hepatitis and its complications."/>
  <result pre="with the existing National programmes towards awareness, prevention, diagnosis, and" exact="treatment" post="for viral hepatitis. Develop a web-based &quot;Viral Hepatitis Information"/>
  <result pre="the recent developments pertaining to the management of chronic HCV" exact="infection" post="with DAA therapy at primary healthcare level, it is"/>
  <result pre="in order to avoid their misuse. Conclusion Management of HCV" exact="infection" post="is a challenge for both hepatologists and virologists alike."/>
  <result pre="alarming and, therefore, it is imperative to performin vitro RAS" exact="testing" post="especially in patients on DAA therapy who fail to"/>
  <result pre="2BeaulieuPLTsantrizosYSInhibitors of the HCV NS5B polymerase: New hope for the" exact="treatment" post="of hepatitis C infectionsCurr Opin Investig Drugs2004583850 3AshfaqUAJavedTRehmanSNawazZRiazuddinSAn overview"/>
  <result pre="29LavanchyDEvolving epidemiology of hepatitis C virusClin Microbiol Infect2011171071521091831 30Hepatitis C--global" exact="prevalence" post="(update)Wkly Epidemiol Rec199974425710645164 31NerrienetEPouillotRLachenalGNjouomRMfoupouendounJBilongCet al.Hepatitis C virus infection in"/>
  <result pre="30Hepatitis C--global prevalence (update)Wkly Epidemiol Rec199974425710645164 31NerrienetEPouillotRLachenalGNjouomRMfoupouendounJBilongCet al.Hepatitis C virus" exact="infection" post="in cameroon: A cohort-effectJ Med Virol2005762081415834878 32GuerraJGarenneMMohamedMKFontanetAHCV burden of"/>
  <result pre="infection in cameroon: A cohort-effectJ Med Virol2005762081415834878 32GuerraJGarenneMMohamedMKFontanetAHCV burden of" exact="infection" post="in Egypt: Results from a nationwide surveyJ Viral Hepat201219560722762140"/>
  <result pre="C genotype 6 and its managementAliment Pharmacol Ther2011342869621623850 42NguyenMHKeeffeEBPrevalence and" exact="treatment" post="of hepatitis C virus genotypes 4, 5, and 6Clin"/>
  <result pre="header image2015cited 2018 Jun 25Available from: http://www.lucindaporterrn.com/hepatitis-c-the-evolution-of-treatment/ 48GhanyMGNelsonDRStraderDBDavidLTLeonardBSAn update on" exact="treatment" post="of genotype 1 chronic hepatitis C virus infection: 2011"/>
  <result pre="guide for the use of Boceprevir and Telaprevir for the" exact="treatment" post="of hepatitis CJ Viral Hepatitis201219Suppl 2126 50MannsMCornbergMSofosbuvir: The final"/>
  <result pre="53SchaeferEAChungRTAnti-hepatitis C virus drugs in developmentGastroenterology2012142134022537441 54PockrosPJDirect-acting antivirals for the" exact="treatment" post="of hepatitis C virus infectionLast accessed on 2018 Jun"/>
  <result pre="63WylesDMangiaAChengWShafranSSchwabeCOuyangWet al.Long-term persistence of HCV NS5A resistance associated substitutions after" exact="treatment" post="with the HCV NS5A inhibitor, ledipasvir, without sofosbuvirAntivir Ther2018232293828650844"/>
  <result pre="systematic review and meta-analysis of community and primary-care-based hepatitis C" exact="testing" post="and treatment services that employ direct acting antiviral drug"/>
  <result pre="and meta-analysis of community and primary-care-based hepatitis C testing and" exact="treatment" post="services that employ direct acting antiviral drug treatments?BMC Health"/>
 </snippets>
</snippetsTree>
